vcfirmsdirectory.com

Venture capital · Early stage

Aglaia

Dutch venture investor dedicated to cancer therapeutics, creating and funding young companies that develop oncology drugs. It states that it is not currently considering new opportunities.

BilthovenRegistered · Netherlands
New investments · 12 months
Fund vehiclesPublic
2
2 active · EuVECA
First cheque
Active portfolio
FreeRegistry entries, fund vehicles and filingsPROEverything we enrich: deals, team, events and signals
Updated 8 Nov 2026, 05:09 CETSources: ESMA register · aglaia-oncology.com

Investment activity

Round-by-round activity is part of PRO

See every round Aglaia joined

Monthly deal flow, follow-ons, fund closes and exits.

Key signal this week

See all signals

Is Aglaia right for your round?

Is Aglaia a fit for your round?

Match your sector, round, size and region against where they invest, and see who to approach.

Key stats

Fund vehiclesPublic
2
2 active · EuVECA
ESMA register
On the register sincePublic
2019
23 May 2019
ESMA register of EuVECA managers
First cheque
Core stage
New deals per year
Lead rate
Active portfolio
Exits

Fund cycle Public record

Fund vehicles on public registers (ESMA register).

Aglaia Oncology Fund III Coöperatieve U.A.EuVECA · Active · Netherlands
Aglaia Oncology Growth Opportunity Fund II Coöperatieve U.A.EuVECA · Active · Netherlands
Deployed (new cheques)
Next fund expected

Latest investments

Rounds Aglaia joined, from press and the firm’s own posts.

DateCompanyRoundRound sizeRoleAlongside

Every round Aglaia joined

Round sizes, Aglaia’s role and who invested alongside.

Round-by-round history is part of PRO

Notable portfolio

Cristal TherapeuticsInthera BioscienceMimetasModraSapreme TechnologiesISA PharmaceuticalsMerusSyntargaORCA Therapeutics

Portfolio and exits

Every company Aglaia backed and how the exits played out.

Where the money goes

Share of companies at first investment, from the rounds we track.

Where Aglaia puts its money

Sector, country and stage mix across every first cheque.

Investment team

The investment team

Partners, principals and investors, with their city, focus and how to reach them.

Where to meet Aglaia

Events where Aglaia’s team spoke or showed up, from event programmes, press and the firm’s own posts.

Where to meet Aglaia’s partners

The events they speak at, your next chance to meet them, and which ones founders can get into.

Signals

Register and fund filings are free. Website, team and portfolio changes we pick up are PRO.

23 May 2019RegisterAglaia Management B.V. registered as a EuVECA manager.ESMA register · public record

Founders also look at

Frequently asked questions

Aglaia is based in the Netherlands. It also has an office in Bilthoven.

2 fund vehicles are on public registers (ESMA register), including Aglaia Oncology Fund III Coöperatieve U.A. and Aglaia Oncology Growth Opportunity Fund II Coöperatieve U.A.

Stages: Early stage. Sectors: Biotech, Life sciences. From the firm’s own website.

Seeks promising early inventions that could change how cancer is treated, then matures them into clinical-stage businesses. The team brings long oncology R&D experience, shapes strategy together with founders and helps plan research from first screening through clinical trials, aiming to reach licensing, sale or listing. From the firm’s own website.

Aglaia lists 9 portfolio companies on its website, including Cristal Therapeutics, Inthera Bioscience, Mimetas, Modra and Sapreme Technologies.

Firms whose websites list some of the same companies include Avoro Capital Advisors, BIG VENTURES MANAGEMENT COMPANY, LLC and RA Capital.

Know before Aglaia’s next round is announced.

PRO tracks Aglaia’s filings, hires and portfolio changes the day they land, alongside 3,869 other firms.

AglaiaGet Aglaia’s signals the day they landMonitor

Search the directory

Type a firm's name, a city or a country.